CQS Cayman’s Biogen BIIB Stock Holding History

CQS Cayman’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-25,750	Closed	-$7.47M	–	114
2018 Q2	$7.47M	Hold	25,750	–	–	0.4%	57
2018 Q1	$7.05M	Hold	25,750	–	–	0.33%	63
2017 Q4	$8.2M	Hold	25,750	–	–	0.52%	52
2017 Q3	$8.06M	Hold	25,750	–	–	0.54%	53
2017 Q2	$6.99M	Hold	25,750	–	–	0.48%	57
2017 Q1	$7.04M	Buy	25,750 +1,050	+4%	+$297K	0.53%	59
2016 Q4	$7M	Buy	+24,700	New	+$7.32M	0.56%	51
2016 Q2	–	Sell	-24,600	Closed	-$6.4M	–	134
2016 Q1	$6.4M	Sell	24,600 -28,745	-54%	-$7.59M	0.64%	44
2015 Q4	$16.3M	Buy	53,345 +47,345	+789%	+$13.6M	1.13%	23
2015 Q3	$1.75M	Buy	+6,000	New	+$1.98M	0.15%	94
2015 Q2	–	Sell	-1,140	Closed	-$481K	–	179
2015 Q1	$481K	Buy	+1,140	New	+$449K	0.02%	188

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

CQS Cayman's BIIB Position: Q3 2018 in Review

CQS Cayman sold out of Biogen (BIIB) in Q3 2018, closing a stake of 25,750 shares — an estimated $7.47M sold.

CQS Cayman first reported a position in BIIB in Q1 2015 and held it in 11 quarters. The position peaked at $16.3M in Q4 2015. 1,145 funds tracked by Wall St. Rank hold BIIB as of Q3 2018.

CQS Cayman reported no remaining Biogen position as of Q3 2018 after selling out during the quarter.
CQS Cayman sold 25,750 Biogen shares in Q3 2018, an estimated $7.47M.
CQS Cayman first reported a position in Biogen in Q1 2015 and held it in 11 quarters.
CQS Cayman's Biogen position peaked at $16.3M in Q4 2015.
1,145 funds tracked by Wall St. Rank held Biogen as of Q3 2018.

Based on CQS Cayman's 13F filing for Q3 2018, filed 9 Nov 2018.